Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence

Table 2 Meta-analysis summary

Endpoint	Pooled OR	95%CI lower	95%CI upper	I² (%)	τ²	P value (Q test)
MPR	0.28	0.19	0.41	0.0	0.0	0.8188
ORR	0.54	0.25	1.14	71.4	0.89	0.0004
pCR	0.26	0.11	0.66	76.5	1.57	< 0.0001
Resection rate	5.37	2.70	10.66	62.3	0.87	< 0.0006
Grade 3-4 TRAEs	0.33	0.22	0.50	3.5	0.02	0.4725

Pooled ORs and 95%CIs for each outcome using a random-effects model. Heterogeneity is assessed via I², τ², and Cochran’s Q test. OR: Odds ratio; 95%CI: 95% confidence interval; pCR: Pathological complete response; MPR: Major pathological response; ORR: Overall response rate; TRAE: Treatment-related adverse event.